Review of evidence concerning PSA screening for prostate cancer has limitations as basis for policy development

Evidence-Based Medicine

Volumn 18, Issue 2, 2013, Pages 75-76

  Etzioni, Ruth D ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER SCREENING; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HUMAN; MALE; NOTE; PROSTATE CANCER;

EID: 85027939928     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/eb-2012-100803     Document Type: Note

References (5)

1. Hanley JA. Measuring mortality reductions in cancer screening trials. Epidemiol Rev 2011;33:36-45.
2. Pinsky PF, Black A, Kramer BS, et al. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials 2010;7:303-11.
3. Gulati R, Tsodikov A, Wever EM, et al. The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control 2012;23:827-35.
4. Gulati R, Mariotto AB, Chen S, et al. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol 2011;64:1412-17.
5. Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009;101:374-83.